Muciclar

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Muciclar

Property Description
Active ingredient Ambroxol hydrochloride
Pharmacological class Mucolytic and Secretolytic Agent
Common use Facilitating the clearance of mucus from airways
Origin Synthetic compound

What Type of Medicine is Muciclar?

Muciclar is a medicinal preparation whose core active component is the Ambroxol hydrochloride (INN). It is explicitly classified as a mucolytic agent and a secretolytic agent, placing it within the pharmacological group of respiratory drugs designed to manage conditions involving overly viscous secretions. This classification is clinically recognized for its effectiveness in addressing respiratory conditions where the mucus is thick and difficult to expel. Ambroxol is a synthetic compound, derived as a metabolite of the secretolytic agent bromhexine.


Composition, Origin, and Available Forms

The composition of Muciclar is based on Ambroxol hydrochloride as the single active ingredient. As a synthetic entity, its pharmacological properties are well-documented. Muciclar is typically found in a variety of pharmaceutical dosage forms to accommodate different patient needs and routes of administration, commonly including syrup, oral solutions, and tablets. The syrup and oral solution forms are often preferred for use in pediatric patient groups due to ease of swallowing, establishing a key differentiating factor in its market positioning. This range of forms ensures that the active component can be delivered efficiently via the oral route, providing general systemic support for mucus clearance.


What is Muciclar's General Purpose?

The general therapeutic purpose of Muciclar is to support the body in effectively clearing the airways when they are obstructed by heavy or thick mucus. It achieves this by chemically inducing the liquefaction of mucus, a process that breaks down the structural components responsible for high viscosity. This action supports improved mucociliary clearance, the natural transport system that moves secretions out of the respiratory tract. The ultimate benefit is facilitating easier breathing and making coughs more productive, which helps to resolve the uncomfortable feeling of chest congestion.

What side effects are possible with Muciclar?

Possible Side Effects and Safety Information

The safety profile of Muciclar (Ambroxol hydrochloride) is based on regulatory documentation that outlines documented adverse reactions and necessary safety precautions.

Adverse Reactions

Adverse reactions are primarily categorized by the system-organ class affected, with most common effects being gastrointestinal.

Frequency System-Organ Class Specific Reactions
Common (up to 1 in 10) Nervous System, Respiratory/GI Dysgeusia (impaired taste), hypoesthesia of the oral cavity/pharynx, Nausea
Uncommon (up to 1 in 100) Gastrointestinal Vomiting, Diarrhea, Dyspepsia, Abdominal pain, Dry mouth
Rare (up to 1 in 1,000) Immune System, Skin, Nervous System Hypersensitivity reactions, Skin rashes, Urticaria, Headache
Not Known (cannot be estimated) Immune System, Skin Severe Cutaneous Adverse Reactions (SCARs) including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN); Anaphylactic reactions (including shock); Angioedema; Bronchial obstruction

Key Safety Warnings and Restrictions

Muciclar is subject to specific regulatory limitations and contraindications:

  • Children Under 2 Years: Oral forms are contraindicated due to the risk of bronchial obstruction, given the limited capacity of this age group to clear secretions.
  • Severe Organ Dysfunction: The medicine is contraindicated in patients with severe changes to liver and/or kidney function.
  • Severe Skin Reactions: If signs of a progressive skin rash (sometimes with blisters or mucosal lesions) occur, treatment must be discontinued immediately and medical advice sought. The initial phases of SCARs may resemble flu-like symptoms.
  • Pregnancy and Breastfeeding: Use is not recommended during the first trimester of pregnancy and is generally not recommended during breastfeeding.

Safety monitoring includes immediate cessation of the drug if a progressive skin rash develops. Excipients in certain formulations, such as sorbitol and ethanol, carry additional cautionary notes for individuals with conditions like hereditary fructose intolerance or alcoholism.

Overdose and Emergency Response

Overdose and When to Seek Help

The information below is based strictly on descriptions found in official government regulatory documents regarding overexposure to Muciclar (Ambroxol hydrochloride).

Documented Manifestations and Outcomes

Official regulatory information states that symptoms of overdose are typically an extension of known undesirable effects, primarily involving the gastrointestinal system. Commonly reported manifestations include restlessness and diarrhoea. In documented human cases, serious symptoms were not recorded. However, pre-clinical data cited in official labeling notes that in situations of extreme overdosage, clinical signs may involve hypotension (low blood pressure) and excessive salivation (sialorrhea).

Required Emergency Actions

The primary action mandated by regulatory authorities is to seek medical attention or consult a doctor immediately if more than the recommended dosage has been taken. Management of overdose is specified to be mainly symptomatic; official prescribing information states that no specific antidote is known.

Specific procedures like gastric lavage are not generally indicated and are reserved only for cases of extreme overdosage.

Furthermore, official government guidance mandates that the medication must be discontinued immediately and medical advice sought if any signs of a progressive skin rash or mucosal lesions appear, as these could indicate a severe adverse reaction.

Therapeutic Uses of Muciclar

What Muciclar Treats: Main Uses and Benefits

Muciclar (Ambroxol) is commonly used to help with managing the symptoms of congestion caused by excessive mucus, supporting symptomatic management across several domains. It is considered relevant in conditions where patients experience symptoms related to physical discomfort from excessive, thick phlegm. The medication may be used as part of symptomatic management in conditions presenting with systemic or localized discomfort, such as acute and chronic bronchitis and bronchiectasis, as well as situations involving the symptomatic phase of certain acute infections.

The core benefit contributes to improved comfort by assisting with the body's natural processes for managing symptoms that create noticeable physiological strain. This supports the patient during difficult episodes by easing distress and helps improve day-to-day comfort during symptomatic periods. Ambroxol also plays a role in managing localized discomfort and pain in the throat, symptoms that may become more disruptive during periods of heightened symptoms.

“This approach offers symptomatic relief that helps patients cope more steadily with symptom fluctuations and physical strain.”


Quick Fact: Used for Managing Symptoms Related to Respiratory Congestion Muciclar is commonly used to help with managing the symptom cluster of symptoms related to physical discomfort and associated symptoms that interfere with daily functioning, supporting improved comfort.

Eligibility and Restrictions for Use

Who Can and Cannot Use Muciclar?

This section outlines the eligibility and non-eligibility requirements for Muciclar (Ambroxol hydrochloride), as defined by official government regulatory documents.


Contraindicated and Restricted Populations

Classification Population/Condition Regulatory Requirement
Absolute Contraindication Known hypersensitivity to ambroxol or excipients Prohibited
Absolute Contraindication Children under two (2) years of age Prohibited for most oral formulations
Not Recommended First trimester of pregnancy (first 28 weeks) Discouraged
Not Recommended Females who are breastfeeding Discouraged

Conditional Use and Comorbidities

Official labeling specifies conditions where Muciclar must be used with caution:

  • Serious Organ Impairment: Caution is required for patients with serious hepatic impairment or renal impairment due to the risk of metabolite accumulation.
  • Gastrointestinal History: Use requires caution in individuals with a history of peptic or duodenal ulcers.
  • Airway Motility: Patients with compromised airway motility (e.g., primary ciliary dyskinesia) must use with caution.
  • Hereditary Disorders: Individuals with certain hereditary metabolic disorders (e.g., fructose intolerance) are ineligible due to specific excipients in the product formulation.

Adults and adolescents (over 12 years) are generally considered the standard eligible population.

What should I know about interactions with other medicines?

The regulatory profile for Muciclar (Ambroxol) identifies specific drug-drug and population-dependent interaction constraints, strictly as defined in government regulatory labeling.


Interaction Scope

Property Details
Medicinal Product Categories Antitussives (Cough Suppressants) and specific Antibiotics.
Specific Interacting Medicines Amoxicillin, Cefuroxime, Erythromycin, and Doxycycline.
Interaction-Related Restrictions Strong restriction against co-administration with antitussives.
Population-Specific Notes Severe Renal Impairment and Severe Hepatic Impairment affect drug clearance.

Official Interaction Statements

Co-administration with Cough Suppressants (Antitussives) is subject to a strong regulatory restriction and is generally not recommended. This pharmacodynamic interaction risks the serious airway obstruction of secretions due to the concurrent depression of the cough reflex.

Conversely, administration with certain Antibiotics, including Amoxicillin, Cefuroxime, Erythromycin, and Doxycycline, results in an increase of antibiotic concentrations in bronchopulmonary secretions and mucus.

Official labeling addresses pharmacokinetic alterations in specific populations. Severe Renal Impairment leads to the expected accumulation of hepatic metabolites of the drug. In cases of Severe Hepatic Impairment, the drug's overall clearance is officially documented to be decreased by 20–40%. Regulatory sources consistently state that there are no other clinically relevant unfavourable interactions reported with other medicinal products. No specific timing separation requirements are documented in the labeling.


Connection to the Overall Interaction Profile

The regulatory documents define the product's interaction structure based on one primary pharmacodynamic constraint with antitussives and a notable exposure-modifying effect on certain antibiotics. This profile is supplemented by mandatory cautions detailing population-specific pharmacokinetic alterations, which include the reduced clearance in severe hepatic impairment and the risk of metabolite accumulation in severe renal impairment.

Mechanism of Action

How Muciclar Works

Muciclar (Ambroxol) exerts its pharmacodynamic effects across three principal mechanistic domains to modulate the characteristics of respiratory secretions.


Regulation of Mucus Physical Properties

The compound primarily acts as a secretolytic and mucokinetic agent by stimulating the synthesis and secretion of pulmonary surfactant by type II pneumocytes. Surfactant modifies the early molecular steps that reduce the adhesiveness and viscosity of the mucus layer through decreased surface tension. This action modulates ciliary function and reduces the energy required for mucus transport, resulting in the physiological consequence of increased mucus movement within the airways.


Modulation of Inflammatory Cascades

Muciclar engages mechanisms that influence inflammatory processes by modulating the release of pro-inflammatory cytokines and displaying intrinsic antioxidant properties in respiratory tissues. These effects regulate the signaling cascades induced by specific mediators and promote a shift toward a less active signaling state within targeted pathways, influencing the modulation of previously heightened physiological processes.


Inhibition of Neuronal Signaling

Muciclar's capacity to inhibit voltage-gated sodium ( Na^+) channels in peripheral neurons serves as a mechanism for neuronal pathway adjustment. This ion channel blockade reduces the flux of peripheral neuronal impulses within the Na^+ channel-expressing fibers.

Dosage and Administration Information

The use of Muciclar (Ambroxol hydrochloride) follows specific patterns concerning its administration route and standardized dosing. The medicine is intended for oral use via immediate-release (IR) forms like tablets and solutions, or as a 75 mg extended-release (ER) capsule.

The standard adult regimen for the immediate-release form begins with a higher initial dose of 30 mg three times daily for the first 2 to 3 days. This initial phase is typically followed by a reduction to a maintenance dose of 30 mg twice daily. The extended-release capsule is used once daily at 75 mg. Pediatric dosing is significantly lower and is highly dependent on age, utilizing oral solutions or syrups.

Administration context is also defined for the medication. The medicine should be taken preferably after a meal and with an adequate amount of fluid. The ER capsules must be swallowed whole and must not be chewed or crushed to preserve their intended release profile. Specific dose adjustments are utilized for individuals with severe hepatic or renal impairment, involving either a dose reduction or an extension of the interval between administrations.

This protocol structures the medication's use from a defined initial phase to continued use, clarifying the proper intake conditions and special handling necessary for certain formulations.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Muciclar


Evidence for Use in Acute and Chronic Airway Diseases

The primary research involves Randomized Controlled Trials (RCTs) and meta-analyses focused on the use of Muciclar (Ambroxol) in conditions associated with viscous mucus, such as acute and chronic bronchitis and COPD flare-ups. Studies included adults with long-term stable conditions and adults and children with acute symptoms. Researchers explored changes in fluctuating symptoms and monitored patient-reported outcomes, like the perceived difficulty of moving mucus (expectoration), alongside objective measures of sputum viscosity and the mucociliary clearance rate. Studies reported patterns that described changes in mucus characteristics and were related to the measured values of patient expectoration. Findings were sometimes mixed when researchers monitored more technical measurements of lung function.


Evidence for Symptomatic Management of Acute Cough

Research also explored the use of Muciclar for acute cough related to shorter-term illnesses like the common cold. Evidence comes from short-term clinical trials including adults and children. These trials monitored changes using patient-reported outcomes, such as Visual Analog Scale (VAS) scores for cough severity. The follow-up durations were limited, often lasting only a few days to a week. The data show patterns related to measurements of cough severity, but existing studies provide limited insight into whether these observed effects are due to the compound's effect on mucus or other properties it may possess.


Research Gaps and Patient Populations

The scope of research varies significantly, with some chronic condition trials extending up to two years, primarily examining whether there was an association with a change in the frequency of exacerbations. Clinical research has evaluated the compound in both adults and pediatric patients (including infants), but data for certain groups remain insufficient. Research indicates that the long-term effects are not fully established regarding overall disease progression or mortality outcomes. Findings were mixed on technical lung function tests, and subgroup findings are uncertain when exploring populations outside of the established adult chronic bronchitis study groups.

Key Studies & References

  1. Ambroxol for the treatment of children with acute and chronic respiratory diseases: an overview of efficacy and safety
  2. Ambroxol hydrochloride spray (Luo Runchang®) in the treatment of acute respiratory infectious diseases: a prospective, multicenter, open label, randomized controlled study

Frequently Asked Questions (FAQ)

Common questions about Muciclar (FAQ)

Q: Is Muciclar the same as mucolytic cough syrups?

Muciclar's active ingredient, ambroxol, is classified by regulatory agencies as a mucolytic agent and a secretolytic agent. This means it is a type of medicine specifically designed to help thin and clear mucus. These agents are commonly found in cough syrups used to manage wet, congested coughs.


Q: Does Muciclar help with thick phlegm in the throat?

Muciclar is intended to help address thick respiratory secretions, often referred to as phlegm. According to official product information, its primary goal is to induce the liquefaction of mucus and support mucociliary clearance, which is the body's natural system for moving secretions out of the entire respiratory tract, including the throat.


Q: Can Muciclar cause stomach upset or heartburn?

Gastrointestinal issues are the most commonly reported side effects in clinical trials. Nausea is classified as common. Other reported effects include vomiting, diarrhea, abdominal pain, and dyspepsia (indigestion), which covers symptoms like heartburn. These effects are classified as common (nausea) or uncommon (others) in clinical data.


Q: Is it okay to take Muciclar with my morning coffee?

The drug's administration guidelines specify taking it preferably after a meal and with an adequate amount of fluid. While no specific restriction against caffeine is listed in the interaction data, taking the medication with or after food is the condition described in official labeling to minimize potential gastrointestinal effects.


Q: Are there certain foods or drinks I should avoid while taking Muciclar?

Official regulatory documents focusing on drug-drug interactions state that there are no other clinically relevant unfavourable interactions reported with other medicinal products. This suggests no specific restrictions are placed on most common foods or drinks. The full product information leaflet is the source for detailed guidance regarding administration and potential concerns.


Q: Why is hydration important when taking Muciclar?

Official directions recommend taking the medicine with an adequate amount of fluid. Hydration is important because the drug's mucolytic action, which thins mucus, is supported by an adequate intake of fluids.


Q: Does Muciclar affect birth control pills?

According to the official product information on drug-drug interactions, regulatory sources consistently state that there are no other clinically relevant unfavourable interactions reported with other medicinal products. The lack of reported clinically relevant interactions suggests that Muciclar does not interfere with oral contraceptives, according to official data.


Q: What are the signs that Muciclar is actually working for my condition?

As the drug is intended to increase mucus flow and reduce viscosity, clinical studies relate its use to increased patient reports of productive cough and easier expectoration (clearing mucus). These physical changes are what the medication is designed to facilitate.


Q: Can I take other cough and cold medicines while using Muciclar?

Co-administration with cough suppressants (antitussives) is strongly restricted and generally not recommended due to the risk of serious airway obstruction from accumulated secretions. Regulatory sources state there are no other clinically relevant unfavourable interactions reported with other medicinal products besides antitussives.


Q: Does Muciclar help with sinus congestion related to post-nasal drip?

Muciclar's therapeutic action is to liquefy viscous respiratory secretions. While the drug is not officially indicated for sinus congestion, its effects on mucus properties may assist in managing thick secretions contributing to post-nasal drip.


Q: What is the recommended storage temperature for Muciclar?

Official labeling requires that the medicine be stored at a temperature not exceeding 25 C or 30 C, depending on the formulation and region. It is important that the product is not refrigerated or frozen. The storage temperature range specified on the product packaging should be followed.


Q: What happens if I miss a dose of Muciclar?

Product information describes the standard procedure: if a dose is missed, it should be taken as soon as possible, unless it is almost time for the next dose. Official guidance advises against taking a double dose to compensate for the forgotten dose.


Q: Can I take Muciclar if I have high blood pressure?

While ambroxol alone may not be explicitly contraindicated for high blood pressure, some regulatory documents advise caution when using ambroxol-containing products in patients with severe cardiovascular disorders or hypertension. Individuals with high blood pressure are advised to consult a healthcare professional regarding their specific medical status.


Q: What is the difference between Muciclar and medicines like Mucinex?

Muciclar's active ingredient is ambroxol, which is categorized as a mucolytic that breaks down mucus structure. In contrast, medicines like Mucinex often contain guaifenesin, which is an expectorant that increases the volume of water in the airways to help move mucus. The two active ingredients belong to different pharmacological classes, though both are used to manage respiratory secretions.


Q: What should I do if a side effect from Muciclar seems severe?

Official safety warnings state that if signs of a progressive skin rash occur, which can sometimes include blisters or mucosal lesions, treatment must be discontinued immediately. If signs of a severe skin reaction occur, medical attention must be sought immediately, as these symptoms can indicate a rare but serious adverse reaction.


Q: Does Muciclar have an expiry date that matters?

Yes, Muciclar has a specified shelf life and expiry date that must be observed. Official regulations require that expired or unused medication be disposed of in accordance with local requirements, and should not be discarded via household waste or wastewater.


Q: Is there a generic version of Muciclar available?

The active ingredient in Muciclar is Ambroxol hydrochloride. Because ambroxol is the official name of the drug substance, it is widely available globally under various generic and other brand names. The availability of generic forms depends on the specific region and market authorization.


Q: Can I take Muciclar if I have asthma or COPD?

Research has included ambroxol in studies related to conditions such as chronic bronchitis and COPD flare-ups. However, individuals with severe or uncontrolled asthma or COPD are advised to have their specific medical status reviewed by a healthcare professional.


Q: What is the usual duration of treatment with Muciclar?

For acute respiratory tract disorders, treatment is generally for a limited period, often up to about 14 days. If symptoms do not improve after approximately five days of self-treatment, official product information advises seeking medical consultation. For chronic conditions, the treatment duration will be established based on the patient's individual condition.


Q: Can Muciclar be taken on an empty stomach?

While some official labeling states that Muciclar can be administered with or without food, it is generally recommended to take it with or after a meal. This preference is usually stated to help minimize the potential for gastrointestinal side effects, such as nausea or stomach upset.


Q: Does Muciclar interact with any herbal supplements?

Official regulatory documents on drug interactions do not report any clinically relevant unfavourable interactions with other medicines. However, some product information advises that a patient’s full history, including the use of all over-the-counter products and herbal supplements, be reviewed.


Q: Is Muciclar used for conditions other than respiratory issues?

Muciclar is primarily classified as a respiratory medicine for clearing mucus. However, due to its local anesthetic property—which is one of its mechanisms of action—its active ingredient, ambroxol, is also utilized in some formulations (like lozenges) for the temporary symptomatic treatment of sore throat.


Q: Are there common user complaints about Muciclar’s taste or texture?

According to the list of side effects, the most common nervous system effect reported is Dysgeusia (impaired taste). The active ingredient, ambroxol, has a naturally bitter taste, which is why manufacturers use specific flavorings and textures to mask it, especially in liquid and syrup formulations.


Q: Is Muciclar addictive or habit-forming?

Muciclar (Ambroxol) is classified as a mucolytic agent. This pharmacological class is designed to thin mucus and is not associated with effects on the central nervous system (CNS) that would lead to addiction or habit formation.


Q: Is Muciclar a prescription-only medicine or can I buy it over the counter?

The status of Muciclar varies globally and often depends on the dosage form and concentration. In many regions, lower-strength syrup or tablet forms of ambroxol are available for purchase over-the-counter (OTC) without a prescription. Higher doses or specialized formulations may require a prescription.

How should Muciclar be stored and disposed of?

How to Store and Dispose of Muciclar?

Muciclar (Carbocisteine) must be stored strictly according to its official regulatory labeling to ensure product stability and safety. The medicine must be stored at a temperature not exceeding 25 C or 30 C and should not be refrigerated or frozen. Protection from direct heat and light is required for some formulations. It is mandatory to store the medicine out of the sight and reach of children.

Disposal Requirements

Any unused or expired product must be disposed of in accordance with local requirements. Official regulations state that medicines should not be disposed of via wastewater or household waste to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Muciclar found in:

A-Z Index: